
Nawab Qizilbash

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/933253/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Antipsychotic treatment patterns in Alzheimer's disease patients with agitation: a cohort study using the UK clinical practice research datalink. Current Medical Research and Opinion, 2022, , 1-8.	1.9	0
2	Localised neuropathic pain in the primary care setting: a cross-sectional study of prevalence, clinical characteristics, treatment patterns, quality of life and sleep performance. Current Medical Research and Opinion, 2021, 37, 293-302.	1.9	8
3	Blood cholesterol and risk of dementia in more than 1·8 million people over two decades: a retrospective cohort study. The Lancet Healthy Longevity, 2021, 2, e498-e506.	4.6	53
4	Effectiveness of Additional Risk Minimization Measures for Atezolizumab in the European Union. Pharmaceutical Medicine, 2021, 35, 339-351.	1.9	0
5	Pre/post effectiveness evaluation of updated additional risk minimisation measures for an orphan disease: Myozyme (alglucosidase alfa) Safety Information Packet. Pharmacoepidemiology and Drug Safety, 2020, 29, 103-110.	1.9	2
6	Association of anthropometry and weight change with risk of dementia and its major subtypes: A metaâ€analysis consisting 2.8 million adults with 57 294 cases of dementia. Obesity Reviews, 2020, 21, e12989.	6.5	62
7	Linking process indicators and clinical/safety outcomes to assess the effectiveness of abatacept () Tj ETQq1 Safety, 2020, 29, 664-674.	1 0.784314 rgB 1.9	3T /Overlock 3
8	Raised blood pressure and risk of dementia. European Heart Journal, 2019, 40, 785-786.	2.2	5
9	Are risk minimization measures for approved drugs in Europe effective? A systematic review. Expert Opinion on Drug Safety, 2019, 18, 443-454.	2.4	21
10	A review of studies evaluating the effectiveness of risk minimisation measures in Europe using the European Union electronic Register of Postâ€Authorization Studies. Pharmacoepidemiology and Drug Safety, 2018, 27, 695-706.	1.9	30
11	A Retrospective Study of the Clinical Burden of Hospitalized All-Cause and Pneumococcal Pneumonia in Canada. Canadian Respiratory Journal, 2016, 2016, 1-10.	1.6	23
12	Does midlife obesity really lower dementia risk? – Authors' reply. Lancet Diabetes and Endocrinology,the, 2015, 3, 501-502.	11.4	2
13	BMI and risk of dementia in two million people over two decades: a retrospective cohort study. Lancet Diabetes and Endocrinology,the, 2015, 3, 431-436.	11.4	343
14	Benefit–Risk Analysis of Glatiramer Acetate for Relapsing-Remitting and Clinically Isolated Syndrome Multiple Sclerosis. Clinical Therapeutics, 2012, 34, 159-176.e5.	2.5	26
15	Body-mass index and cause-specific mortality in 900â€^000 adults: collaborative analyses of 57 prospective studies. Lancet, The, 2009, 373, 1083-1096.	13.7	3,779
16	Risk of ischaemic cardiovascular events from selective cyclooxygenaseâ€2 inhibitors in osteoarthritis. Pharmacoepidemiology and Drug Safety, 2008, 17, 601-608.	1.9	21
17	Progression of benign prostatic hyperplasia: systematic review of the placebo arms of clinical trials. BJU International, 2008, 102, 981-986.	2.5	43
18	Cancer risks in thiazolidinedione users compared to other anti-diabetic agents. Pharmacoepidemiology and Drug Safety, 2007, 16, 485-492.	1.9	93